IHL.AX Incannex Healthcare ASX pre-market 20 Feb 2026: 61.36M shares active

IHL.AX stock opened pre-market on 20 Feb 2026 at A$0.047 and trades at A$0.041 after a one-day drop of -10.87%, driven by heavy volume of 61,360,016 shares. As one of the most active ASX names this session, Incannex Healthcare Limited (IHL.AX) shows a relative volume near 9.55x its average, signalling elevated trader attention ahead of catalysts. We track clinical progress, cash metrics and short-term technical levels to frame the most active flow and investor risks.

Pre-market price, range and volume for IHL.AX stock

IHL.AX stock trades at A$0.041 pre-market with a session low of A$0.041 and a high of A$0.051, and an intraday swing reflecting volatile order flow; the previous close was A$0.046. Volume is 61,360,016 versus an average of 6,427,691, producing a relative volume of 9.55, which confirms the ‘most active’ tag and suggests large retail or block activity influenced the move.

Fundamentals and valuation snapshot for Incannex Healthcare (IHL.AX stock analysis)

Incannex shows an EPS of -1.30 and a negative PE near -3.15, reflecting losses from R&D and development-stage operations; book value per share is A$0.05 and price-to-book is 0.75, below healthcare peers. Market capitalisation is A$14,255,927.00 on 347,705,540 shares outstanding, and the current ratio of 9.02 suggests short-term liquidity is adequate while cash per share is A$0.02.

Clinical pipeline and sector drivers in IHL.AX stock outlook

Incannex develops cannabinoid and psychedelic therapeutics, with assets at Phase IIa (IHL-42X, Psi-GAD) and completed Phase IIa programs across dermatology and GI indications; that pipeline keeps investor focus on binary trial outcomes. The broader Healthcare sector on the ASX has an average PE near 27.53, so IHL.AX’s valuation is tied more to trial readouts and licensing prospects than to standard earnings multiples.

Technical picture, momentum and trading risk for IHL.AX stock

Price averages show a 50-day mean of A$0.0649 and 200-day mean of A$0.10285, indicating a downtrend; the current price at A$0.041 sits at the 52-week low. High volume and a one-day drop of -10.87% increase short-term volatility; traders should watch support at A$0.041 and a first resistance band near A$0.06. Average daily range and liquidity profile mean slippage can be material for larger orders.

Meyka AI grade, model forecast and analyst context for IHL.AX stock

Meyka AI rates IHL.AX with a score out of 100: 64.88 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month base case price of A$0.06, implying an upside of +46.34% from the current A$0.041, and a conservative downside case at A$0.025. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

IHL.AX stock is one of the ASX’s most active pre-market names on 20 Feb 2026, trading at A$0.041 on 61,360,016 shares and a sharp one-day move of -10.87%. Activity reflects headline-driven trading and ongoing attention to the company’s Phase II pipeline rather than near-term earnings. Key fundamentals show negative EPS (-1.30) and a low price-to-book (0.75), while the balance sheet and current ratio (9.02) reduce short-term solvency risk. For traders the immediate story is liquidity and volatility; for longer-term investors the outcome of clinical trials and potential licensing deals will drive value. Meyka AI’s forecast model projects A$0.06 in 12 months, implying roughly +46.34% from today’s level, but this projection is model-based and not guaranteed. We link market moves to trial, licensing and funding news, and recommend close monitoring of volume, trial updates and cash runway before increasing position size. For further real-time data see Investing.com report and our internal coverage at Meyka AI stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.